Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial Academic Article uri icon

Overview

MeSH Major

  • Janus Kinases
  • Pyrazoles
  • Spleen

abstract

  • Ruxolitinib-treated patients achieved clinically meaningful improvements in myelofibrosis-related symptoms and QoL, but patients receiving placebo reported worsening of symptoms and other PROs.

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4979167

Digital Object Identifier (DOI)

  • 10.1200/JCO.2012.44.4489

PubMed ID

  • 23423753

Additional Document Info

start page

  • 1285

end page

  • 92

volume

  • 31

number

  • 10